Martin E. Schmieg - 01 Aug 2022 Form 3 Insider Report for BriaCell Therapeutics Corp. (BCTX)

Role
Director
Signature
/s/ Martin E. Schmieg
Issuer symbol
BCTX
Transactions as of
01 Aug 2022
Transactions value $
$0
Form type
3
Filing time
01 Aug 2022, 16:10:33 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BCTX Common Shares 575 01 Aug 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BCTX Option (Right to Buy) 01 Aug 2022 Common Shares 25,000 $4.24 Direct
holding BCTX Option (Right to Buy) 01 Aug 2022 Common Shares 50,000 $8.47 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Option vests quarterly for 2 years from the date of grant.